No definition available.
Endpoint definition
↥
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
520210 |
1. Apply sex-specific ruleNone |
520210 |
2. Check conditionsNone |
520210 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
227 |
4. Check minimum number of eventsNone |
227 |
5. Include endpointsNone |
227 |
6. Filter based on genotype QC (FinnGen only) |
227 |
Control definitions (FinnGen only)
- Control exclude
- L12_DISORDSKINAPPENDIX
Extra metadata
- Level in the ICD hierarchy
- 4
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- L60
- Name in latin
- Dystrophia unguium
Similar endpoints
↥List of similar endpoints to
Nail dystrophy
based on the number of shared cases.
Similar with more cases:
- Nail disorders
- Disorders of skin appendages
- Diseases of the skin and subcutaneous tissue
- Any event in hilmo or specialist outpatient
- Any prescribed medicine buy
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 1588 | 915 | 667 |
| Only index persons | 1462 | 851 | 611 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.02 | 0.03 | 0.02 |
| Only index persons | 0.03 | 0.03 | 0.02 |
| Median age at first event (years) | |||
| Whole population | 45.42 | 50.45 | 38.41 |
| Only index persons | 45.88 | 50.41 | 39.58 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 227 | 134 | 93 |
| Unadjusted period prevalence (%) | 0.04 | 0.05 | 0.04 |
| Median age at first event (years) | 53.57 | 53.41 | 53.79 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS (R11)
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 203
- Matched controls
- 2028
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
L60.3
ICD-10 Finland
Nail dystrophy
+∞
256.3
188
*
L60.9
ICD-10 Finland
Nail disorder, unspecified
46.1
14.3
17
*
QDH00
NOMESCO Finland
Avulsion of toe nail
80.7
13.8
15
*
QCH00
NOMESCO Finland
Avulsion of finger nail
126.8
11.5
12
*
D01BA02
ATC
terbinafine; oral; topical
3.1
11.4
76
325
Z50.8
ICD-10 Finland
Care involving use of other rehabilitation procedures
5.5
11.0
33
69
RJ421
NOMESCO Finland
NA
+∞
10.5
10
*
TQX10
NOMESCO Finland
Biopsy of skin and subcutaneous tissue
4.6
10.5
37
93
L60.0
ICD-10 Finland
Ingrowing nail
7.7
10.1
23
33
RJ420
NOMESCO Finland
NA
+∞
9.4
9
*
B35.1
ICD-10 Finland
Tinea unguium
5.5
9.2
27
55
L30.9
ICD-10 Finland
Dermatitis, unspecified
3.2
9.1
53
202
S22
ICPC
Nail symptom/complaint
5.7
8.0
22
42
RJ411
NOMESCO Finland
NA
46.8
7.8
9
*
D01AE16
ATC
amorolfine; topical
3.4
7.6
38
129
L60.1
ICD-10 Finland
Onycholysis
83.0
7.5
8
*
70300
ICD-8 Finland
Diseases of nail, Dystrophia unguium
+∞
7.3
7
*
L17
ICPC
Foot/toe symptom/complaint
2.5
6.7
63
314
R4110
NOMESCO Finland
Physiotherapy
2.4
6.6
63
317
7038A
ICD-9 Finland
Diseases of nail, Other specified diseases of nail[DYSTROPHIA UNGUIUM]
+∞
6.3
6
*
R53
ICD-10 Finland
Malaise and fatigue
2.6
6.1
49
223
L03.0
ICD-10 Finland
Cellulitis of finger and toe
4.0
6.1
23
62
R03AC02
ATC
salbutamol; inhalant
2.1
6.1
114
770
WYA30
NOMESCO Finland
Preparations for expected poor cooperation
4.0
6.0
23
63
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
125
789
2.30
8.66
5.1
4.3
35.2
35.6
g/l
0.26
113
746
66
337
2.35
7.33
3.4
3.3
179.9
137.2
ng/l
0.17
46
253
10
13
8.00
7.17
1.0
1.3
6.1
8.5
u/l
—
5
13
115
754
2.06
6.67
2.6
2.2
81.6
75.9
nmol/l
1.14
102
659
39
174
2.50
5.73
2.4
2.3
36.8
30.8
u/l
0.44
32
144
125
894
1.89
5.19
9.7
7.0
1.2
1.2
mmol/l
0.66
113
753
176
1413
2.09
5.15
5.1
4.0
13.8
11.8
mm/h
1.02
163
1289
18
57
3.34
4.88
1.6
2.6
—
—
—
0
0
29
121
2.60
4.87
2.6
2.6
77.3
137.3
ng/l
1.35
29
108
19
63
3.20
4.80
1.4
2.4
3.4
3.2
g/l
0.22
13
52
53
291
2.07
4.74
3.0
2.8
3.7
2.8
e6/l
0.15
29
156
81
519
1.87
4.63
1.8
1.7
1.3
1.4
mmol/l
0.24
74
426
20
70
3.04
4.63
1.4
2.3
3.9
3.8
g/l
0.02
13
51
20
70
3.04
4.63
1.4
2.3
8.0
7.9
g/l
0.06
14
53
20
70
3.04
4.63
1.4
2.3
—
—
—
0
0
19
65
3.10
4.56
1.3
2.3
10.1
9.8
g/l
0.14
14
59
143
1095
1.83
4.52
10.5
9.3
4.0
4.1
e9/l
0.19
127
966
13
35
3.88
4.43
1.5
1.5
—
—
—
0
0
13
35
3.88
4.43
1.5
1.5
—
—
—
0
0
146
1131
1.82
4.38
5.7
5.0
6.4
6.6
mmol/l
0.61
133
1040
98
681
1.77
4.21
3.0
2.9
—
—
—
0
0
10
23
4.50
4.13
1.1
1.2
—
—
—
0
0
10
23
4.50
4.13
1.1
1.2
—
—
—
0
0
214
1913
3.07
4.10
18.0
13.4
29.4
22.2
mg/l
1.82
185
1476
66
413
1.84
3.98
2.9
2.0
2.4
3.2
mg/l
2.10
57
352
112
819
1.73
3.96
8.1
6.1
1.2
1.2
mmol/l
0.48
104
750
10
24
4.31
3.93
1.1
1.2
—
—
—
0
0
10
24
4.31
3.93
1.1
1.2
—
—
—
0
0
10
24
4.31
3.93
1.1
1.2
—
—
—
0
0
100
714
1.72
3.82
2.2
1.9
102.4
96.9
pmol/l
0.38
44
333
53
315
1.89
3.74
2.9
2.7
0.8
1.1
e6/l
0.53
29
176
13
40
3.39
3.68
1.2
1.2
—
—
—
0
0
106
778
1.68
3.60
4.4
2.4
74.9
110.9
ug/l
3.77
100
706
43
245
1.93
3.42
2.6
2.1
25.5
22.7
%
0.26
36
208
77
525
1.71
3.40
2.9
2.9
0.3
0.4
e6/l
0.28
61
387
8
16
5.14
3.08
1.3
1.1
—
—
—
0
0
14
51
2.86
3.04
1.5
1.6
0.0
0.1
iu/ml
—
5
9
5
5
10.18
2.99
1.0
1.6
—
—
—
0
0
126
1003
1.58
2.86
6.5
6.4
10.9
10.6
umol/l
0.14
121
944
34
192
1.91
2.78
1.6
1.8
—
—
—
0
0
45
280
1.76
2.70
1.6
1.8
—
—
—
0
0
7
15
4.78
2.61
1.0
1.0
—
—
—
0
0
34
197
1.85
2.57
1.6
1.8
—
—
—
0
0
168
1449
1.61
2.55
4.7
3.8
14.4
14.9
pmol/l
1.44
157
1300
11
40
2.84
2.41
1.5
1.4
—
—
—
0
0
22
112
2.07
2.40
1.3
1.2
218.2
137.5
iu/ml
0.31
11
46
195
1761
1.76
2.32
5.7
4.6
2.0
1.9
mu/l
0.35
181
1596
13
54
2.49
2.24
3.6
2.7
—
—
—
0
0
11
43
2.64
2.13
1.4
1.2
—
—
—
0
0
8
25
3.28
2.11
1.0
1.1
—
—
—
0
0
73
543
1.51
2.11
1.8
2.0
169.6
177.2
u/l
0.07
68
510
82
627
1.48
2.07
3.1
2.9
2.3
2.4
mmol/l
0.80
72
543
7
20
3.58
2.07
2.6
4.1
—
—
—
0
0
109
882
1.45
2.05
3.8
4.3
—
—
—
0
0
67
493
1.51
2.03
2.2
2.7
341.6
7827.4
umol/l
2.40
62
425
8
26
3.15
2.03
1.0
1.1
—
—
—
0
0
61
441
1.52
2.01
2.6
2.4
—
—
—
0
0
12
51
2.43
1.98
1.2
1.5
31.7
24.8
iu/l
0.25
12
46
5
11
4.62
1.95
1.2
1.2
—
—
—
0
0
36
530
0.62
1.89
3.7
4.0
0.0
0.0
estimate
0.50
15
192
45
308
1.58
1.88
1.5
1.3
20.1
10.6
u/ml
—
10
118
31
194
1.69
1.84
11.8
10.5
2.5
1.4
mmol/l
0.70
23
157
(3016894) Varicella zoster virus DNA [Presence] in Cerebral spinal fluid by NAA with probe detection
5
12
4.23
1.83
1.0
1.3
—
—
—
0
0
57
414
1.50
1.83
2.5
1.9
1.0
1.1
mg/l
0.07
45
314
9
35
2.63
1.82
1.7
1.4
—
—
—
0
0
192
1759
1.59
1.76
6.2
5.6
39.8
39.9
mmol/mol
0.08
181
1629
60
446
1.47
1.71
1.3
1.2
0.8
1.5
u/ml
0.62
11
118
7
25
2.86
1.66
1.1
1.1
—
—
—
0
0
6
20
3.05
1.59
1.2
1.2
—
—
—
0
0
13
65
2.06
1.52
2.1
2.1
63.1
375.6
ug/l
2.24
13
60
6
21
2.91
1.51
1.2
1.3
—
—
—
0
0
6
21
2.91
1.51
1.2
3.0
—
10.9
—
0
6
6
21
2.91
1.51
1.0
1.1
—
—
—
0
0
11
52
2.17
1.47
1.0
1.3
—
—
—
0
0
214
2035
1.90
1.45
14.5
10.2
28.4
26.9
u/l
0.27
209
1955
5
16
3.17
1.44
1.0
1.3
2.0
1.7
mmol/l
—
5
16
143
1263
1.36
1.41
3.3
3.1
35.2
45.4
u/l
2.54
135
1183
187
1727
1.47
1.40
25.4
14.3
40.2
40.2
%
0.06
142
1262
56
427
1.41
1.39
1.5
1.5
19.3
21.5
nmol/l
0.59
51
350
9
42
2.19
1.35
2.1
1.8
—
—
—
0
0
44
323
1.45
1.33
1.4
1.7
920.7
1213.0
nmol/l
2.26
36
236
61
756
0.74
1.24
3.5
3.8
—
—
—
0
0
44
329
1.42
1.21
2.0
2.9
2.4
2.5
mmol/l
0.38
35
288
16
94
1.76
1.21
1.3
1.8
—
—
—
0
0
197
1854
1.47
1.17
5.3
4.5
5.9
5.9
mmol/l
0.52
184
1682
12
65
1.89
1.16
1.4
1.8
—
—
—
0
0
42
316
1.40
1.12
1.6
1.3
9.9
34.0
iu/ml
—
10
104
15
238
0.60
1.08
4.8
6.8
—
—
—
0
0
191
1795
1.40
1.07
16.0
13.0
86.2
82.9
ml/min/173m2
1.21
175
1450
135
1211
1.28
1.05
3.3
3.0
—
—
—
0
0
5
22
2.30
1.04
1.0
1.9
—
—
—
0
0
7
34
2.09
1.04
1.6
1.3
—
—
—
0
0
27
190
1.48
1.03
2.1
2.1
—
—
—
0
0
19
124
1.58
1.00
2.4
1.5
—
—
—
0
0
201
1911
1.45
0.99
5.6
4.9
2.7
2.8
mmol/l
1.15
186
1748
12
69
1.78
0.98
1.5
1.9
—
—
—
0
0
14
85
1.69
0.96
21.3
10.6
26.2
25.0
mmol/l
0.70
14
80
63
518
1.30
0.96
2.5
3.1
729.0
1178.5
ng/l
1.26
53
434
6
27
2.25
0.94
1.0
1.2
—
—
—
0
0
6
28
2.17
0.92
1.2
1.0
—
—
—
0
0
198
1885
1.39
0.89
5.0
4.3
4.6
4.7
mmol/l
0.79
184
1731
8
43
1.89
0.88
1.1
1.4
—
—
—
0
0
37
285
1.36
0.88
1.7
1.4
—
—
—
0
0
8
44
1.85
0.87
1.5
1.2
—
—
—
0
0
8
46
1.77
0.83
1.1
1.4
—
—
—
0
0
6
33
1.84
0.79
5.2
2.9
—
981.2
—
0
6
10
160
0.61
0.77
2.2
3.7
1.2
1.2
mmol/l
—
10
144
6
34
1.78
0.77
1.3
1.2
—
—
—
0
0
196
1878
1.32
0.71
4.9
4.3
1.5
1.5
mmol/l
0.24
181
1720
13
85
1.56
0.70
3.0
1.9
—
—
—
0
0
27
208
1.34
0.66
2.4
2.3
—
—
—
0
0
8
49
1.66
0.63
1.1
1.4
—
—
—
0
0
15
105
1.46
0.62
2.9
2.7
5.3
5.1
kpa
0.22
15
98
0
20
0.00
0.60
0.0
1.3
—
—
—
0
0
8
52
1.56
0.60
2.3
1.4
—
—
—
0
0
47
396
1.24
0.59
1.8
1.8
405.0
452.6
pmol/l
0.92
37
326
8
54
1.50
0.58
1.4
1.2
—
—
—
0
0
8
54
1.50
0.58
3.1
4.0
—
2.7
—
0
10
5
88
0.56
0.57
1.2
1.5
—
—
—
0
0
8
55
1.47
0.56
3.4
4.2
39.5
70.8
mg/l
—
8
42
28
223
1.29
0.56
23.2
18.9
1.0
1.2
inr
—
6
29
15
108
1.42
0.54
1.0
1.0
—
—
—
0
0
38
316
1.24
0.54
4.1
2.9
0.6
0.8
ug/l
0.85
31
198
43
364
1.22
0.52
2.0
1.5
—
—
—
0
0
14
101
1.41
0.51
19.6
6.4
26.7
25.1
mmol/l
0.70
14
101
7
49
1.44
0.46
1.1
1.5
—
—
—
0
0
5
33
1.53
0.41
1.2
1.5
—
—
—
0
0
0
16
0.00
0.41
0.0
1.0
—
—
—
0
0
0
17
0.00
0.41
0.0
1.1
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
14
108
1.32
0.36
3.6
2.0
—
—
—
0
0
6
45
1.34
0.34
1.2
1.5
—
—
—
0
0
7
54
1.31
0.30
1.4
1.2
—
—
—
0
0
65
598
1.12
0.30
2.3
2.5
73.9
55.1
u/l
0.43
60
546
101
956
1.10
0.27
5.4
5.1
0.0
0.0
estimate
0.00
15
194
23
197
1.19
0.27
3.6
4.3
15.9
27.5
ug/l
0.19
15
166
5
74
0.67
0.26
1.4
2.1
—
—
—
0
0
100
951
1.09
0.24
3.5
3.7
0.0
0.0
estimate
0.00
13
195
101
964
1.09
0.22
3.5
3.8
0.0
0.0
estimate
0.00
14
190
0
12
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
1.2
—
—
—
0
0
0
13
0.00
0.21
0.0
2.3
—
93.6
—
0
13
0
14
0.00
0.20
0.0
1.8
—
—
—
0
0
0
14
0.00
0.20
0.0
3.5
—
—
—
0
0
0
14
0.00
0.20
0.0
1.7
—
—
—
0
0
0
14
0.00
0.20
0.0
1.3
—
—
—
0
0
6
53
1.14
0.19
1.2
1.5
—
—
—
0
0
14
160
0.87
0.14
21.7
7.4
1.2
1.3
mmol/l
0.17
14
153
8
98
0.81
0.14
2.6
2.7
1.8
1.3
%
—
8
98
22
203
1.09
0.10
2.1
3.3
—
—
—
0
0
16
176
0.90
0.10
2.6
1.6
—
—
—
0
0
5
47
1.07
0.09
1.8
1.6
—
—
—
0
0
6
54
1.11
0.09
1.2
1.1
—
20.8
—
0
8
71
721
0.98
0.03
2.3
3.7
27.2
33.1
ng/l
0.32
38
503
10
107
0.93
0.02
1.3
1.4
—
—
—
0
0
181
1803
1.02
0.01
4.6
3.9
1.3
1.3
mmol/l
0.49
162
1647
42
426
0.98
0.00
5.1
4.4
22.6
21.5
%
0.20
25
198
11
108
1.02
0.00
1.3
1.4
—
—
—
0
0
24
237
1.01
0.00
4.2
4.3
39.6
31.6
%
1.95
15
147
0
7
0.00
0.00
0.0
2.6
—
214.9
—
0
7
0
6
0.00
0.00
0.0
1.2
—
8.9
—
0
6
0
7
0.00
0.00
0.0
1.7
—
—
—
0
0
0
9
0.00
0.00
0.0
2.3
—
—
—
0
0
0
6
0.00
0.00
0.0
1.3
—
—
—
0
0
5
49
1.02
0.00
1.4
1.9
—
—
—
0
0
0
9
0.00
0.00
0.0
2.3
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
0
6
0.00
0.00
0.0
1.2
—
—
—
0
0
0
6
0.00
0.00
0.0
1.7
—
—
—
0
0
0
5
0.00
0.00
0.0
1.2
—
—
—
0
0
0
8
0.00
0.00
0.0
1.1
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint L12_NAIL_DYSTROPHY and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_NAIL_DYSTROPHY | 1.491 [1.13, 1.97] | 0.005 |
| Birth year | 0.99 [0.98, 1.0] | 0.034 |
During the follow-up period (1.1.1998 — 31.12.2019), 89 out of 782 females with L12_NAIL_DYSTROPHY died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| L12_NAIL_DYSTROPHY | 1.187 [0.87, 1.62] | 0.285 |
| Birth year | 0.988 [0.98, 1.0] | 0.018 |
During the follow-up period (1.1.1998 — 31.12.2019), 56 out of 524 males with L12_NAIL_DYSTROPHY died.
Mortality risk
Mortality risk for people of age
years, who have L12_NAIL_DYSTROPHY.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.129% | 0.238% |
| 5 | 0.734% | 1.34% |
| 10 | 1.892% | 3.472% |
| 15 | 3.565% | 6.6% |
| 20 | 6.123% | 11.305% |
Relationships between endpoints
↥Index endpoint: L12_NAIL_DYSTROPHY – Nail dystrophy
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data